Lunaphore is a pioneer in advanced tissue analysis for cancer diagnostic. Around 20 million cases of cancer are diagnosed worldwide each year. This number is expected to increase by 70% in 2030. Laboratories need to increase rapidity and accuracy to provide fast and reliable diagnostics.
Lunaphore develops an automated tissue analytic machine specialized in tumorous cell detection. The key innovation lies in Lunaphore’s application of a unique microfluidic technology: Fast Fluidic Exchange (FFeX).
Beyond rapidity, this allows the same tissue sample to be used for several microfluidic tests.
The technology produces results that correlate more accurately with real biomarker amounts compared to conventional methods for identifying breast, lung, prostate and colon cancers.
It also performs assays much faster than standard techniques due to short incubation times.
CEO: Ata Tuna Ciftlik
Headquarters: Lausanne, Switzerland
Initial investment date: August 2017
A great event in Zürich for startups and scaleups…